Roos ST, Timmers L, Biesbroek PS, Nijveldt R, Kamp O, van Rossum AC, van Hout GP, Stella PR, Doevendans PA, Knaapen P, et al
doi: 10.1016/j.physbeh.2006.05.048 60 PlamboeckAVeedfaldSDeaconCFHartmannBWettergrenASvendsenLBet al
Specifically, the FDA considered claims that compounded products are generic versions or contain the same active ingredient as FDA-approved GLP-1 drugs are false or misleading
The decision between a 9 percent average (liraglutide at normal dosing) and a 15 percent average (semaglutide at clinical dose) is not just an academic question, as it affects cardiometabolic risk and the degree of protection needed for lean mass
doi: 10.3389/fonc.2023.1171794 Received 22 February 2023 Accepted 10 April 2023 Published 10 May 2023 Volume 13 - 2023 Edited by Pina Ziranu, University of Cagliari, Italy Reviewed by Stefano Mariani, University of Cagliari, Italy Updates Copyright 2023 Ebeling, Kowalczyk, Perez-Vazquez and Mattiola
Food and Drug Administration (FDA) warns consumers eager for weight loss about the practice as well